Lobe Sciences Past Earnings Performance
Past criteria checks 0/6
Lobe Sciences's earnings have been declining at an average annual rate of -12.2%, while the Pharmaceuticals industry saw earnings growing at 26.2% annually. Revenues have been growing at an average rate of 144.4% per year.
Key information
-12.2%
Earnings growth rate
9.3%
EPS growth rate
| Pharmaceuticals Industry Growth | 23.1% |
| Revenue growth rate | 144.4% |
| Return on equity | n/a |
| Net Margin | -291.9% |
| Last Earnings Update | 29 Feb 2024 |
Recent past performance updates
Recent updates
Revenue & Expenses BreakdownBeta
How Lobe Sciences makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 29 Feb 24 | 1 | -3 | 3 | 1 |
| 30 Nov 23 | 1 | -3 | 2 | 1 |
| 31 Aug 23 | 1 | -5 | 3 | 1 |
| 31 May 23 | 0 | -6 | 4 | 0 |
| 28 Feb 23 | 0 | -8 | 4 | 1 |
| 30 Nov 22 | 0 | -10 | 5 | 0 |
| 31 Aug 22 | 0 | -12 | 4 | 0 |
| 31 May 22 | 0 | -22 | 4 | 1 |
| 28 Feb 22 | 0 | -27 | 4 | 1 |
| 30 Nov 21 | 0 | -26 | 5 | 2 |
| 31 Aug 21 | 0 | -23 | 5 | 1 |
| 31 May 21 | 0 | -12 | 5 | 1 |
| 28 Feb 21 | 0 | -6 | 5 | 1 |
| 30 Nov 20 | 0 | -4 | 4 | 0 |
| 31 Aug 20 | 0 | -4 | 4 | 0 |
| 31 May 20 | 0 | -3 | 3 | 0 |
| 29 Feb 20 | 0 | -2 | 4 | 0 |
| 30 Nov 19 | 1 | -1 | 3 | 0 |
| 31 Aug 19 | 1 | -1 | 3 | 0 |
| 31 Aug 18 | 1 | -11 | 3 | 0 |
Quality Earnings: LOBE is currently unprofitable.
Growing Profit Margin: LOBE is currently unprofitable.
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: LOBE is unprofitable, and losses have increased over the past 5 years at a rate of 12.2% per year.
Accelerating Growth: Unable to compare LOBE's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: LOBE is unprofitable, making it difficult to compare its past year earnings growth to the Pharmaceuticals industry (18.4%).
Return on Equity
High ROE: LOBE's liabilities exceed its assets, so it is difficult to calculate its Return on Equity.